MedTrace Logo

Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination

NCT00961649 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2013-07-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to compare the safety and intraocular pressure (IOP)-lowering efficacy of a new fixed combination of brinzolamide/brimonidine (Brinz/Brim) to:

* its individual components (Brinz and Brim), and
* the concomitant administration of Brinz and Brim (Brinz+Brim).

Conditions

Interventions

DRUG

Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension

DRUG

Brinzolamide ophthalmic suspension, 1%

DRUG

Brimonidine tartrate ophthalmic solution, 0.2%

OTHER

Vehicle

Inactive ingredients used as placebo

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • James Teague, BS, Sr. Clinical Manager · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-02-28
Completion
2010-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00961649 on ClinicalTrials.gov